Atibuclimab (Anti-CD14)

Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD.

• Supplier: Selleck Chemicals
• Product #: A2566
• Sku #: A2566-1mg*5